- International patent filed
- Publication of the Hebrew University – Hadassah Medical Center Title: Augmented antiviral T cell Immunity by oral administration of IMM-124E in preclinic models and a phase I / IIa clinical trial: A method for the prevention and treatment of COVID-19
MELBOURNE, Australia, 08 Oct 2021 (GLOBE NEWSWIRE) – Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on the development and commercialization of oral immunotherapeutics for the prevention and treatment of pathogens Intestinal, is pleased to inform shareholders of a recent publication describing the potential antiviral benefits of IMM-124E in a mouse model and human clinical study. IMM124E, the Company’s proprietary product, is used to manufacture Immuron’s flagship commercial and over-the-counter gastrointestinal and digestive health immune supplements, Travelan® and Protectyn®. The studies were conducted independently by the Hadassah Medical Center, Jerusalem Israel.
The research results were recently published on 1st of October 2021 in the Journal Drug Development Research entitled Augmented antiviral T cell Immunity by oral administration of IMM-124E in preclinic models and a phase I / IIa clinical trial: A method for the prevention and treatment of COVID-19 (https: / / doi.org/10.1002/ddr.21890). The article examines the ability of IMM-124E to promote antiviral T cell responses to interferon-γ (IFNγ) in a preclinical mouse model and in a phase I / IIa clinical study in 5 humans. health volunteers. The objective of the research study was to determine the ability of IMM-124E to promote the responses of antiviral T cells to interferon γ (IFNγ). In the preclinical study, mice were administered orally with HBC for 5 days and tested for the number of T cell clones secreting IFNγ in response to the viral antigens of swine flu, Nova flu – Caledonia and cytomegalovirus. The reported data suggest that IMM124E improves antiviral immunity among the viral strains tested. A similar response was observed in the human study. Healthy volunteers were recruited and received IMM-124E at a daily dose of 600 mg for four consecutive days and 1200 mg for an additional day. Blood samples were taken before and after treatment with IMM-124E and tested for the number of T cell clones secreting IFNγ in response to viral antigens of SARS-CoV-2 and hepatitis B virus. The data Preliminary clinical reports suggest that a similar effect has been observed in humans by increasing antiviral responses against COVID-19 and hepatitis B. Although more in-depth and detailed investigations are needed to further validate the results, it is This is very encouraging research.
The company continued the antiviral activities of IMM-124E and these recent published results support the ongoing R&D program. Immuron previously reported research on IMM-124E that demonstrated neutralizing activity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19 (ASX announcements dated May 13, 2021, December 15, 2020 and July 21, 2020).
The company is also pleased to announce that it has filed a Cooperative Patent Application (PCT) to seek international patent protection for IMM-124E which has demonstrated neutralizing activity against the syndrome coronavirus-2. severe acute respiratory (SARS-CoV-2), the virus that causes COVID-19.
This press release has been authorized by the directors of Immuron Limited.
Dr Jerry Kanellos, Ph.D.
Chief Executive Officer
Phone. : +61 (0) 3 9824 5254
For more information visit: http://www.immuron.com